

**Table 3.5**  
**Verified Outcomes (Annualized Percentages) by Race/Ethnicity for SRC Super Cohort Participants<sup>1</sup>**  
 Data as of: March 1, 2019; Events through September 30, 2010 and March 1, 2019

	Race/Ethnicity			
	American Indian/ Alaskan Native	Asian/Pacific Islander	White	Unknown
<b>Outcomes through Extension Study 2005-2010</b>				
<b>Number randomized</b>	583	3663	111511	1877
<b>Mean follow-up (months)</b>	125.1	127.8	143.5	131.0
<b>Cardiovascular<sup>2</sup></b>				
CHD <sup>3</sup>	26 (0.43%)	87 (0.22%)	5240 (0.39%)	81 (0.40%)
CHD death <sup>4</sup>	13 (0.21%)	30 (0.08%)	1813 (0.14%)	35 (0.17%)
Clinical MI	16 (0.26%)	66 (0.17%)	3906 (0.29%)	56 (0.27%)
Angina <sup>5</sup>	23 (0.52%)	56 (0.20%)	3492 (0.39%)	52 (0.36%)
CABG/PTCA	30 (0.49%)	77 (0.20%)	5922 (0.44%)	84 (0.41%)
Carotid artery disease	7 (0.12%)	10 (0.03%)	1074 (0.08%)	20 (0.10%)
Congestive heart failure, WHI <sup>5</sup>	18 (0.41%)	30 (0.11%)	2702 (0.30%)	47 (0.32%)
Stroke	17 (0.28%)	101 (0.26%)	4061 (0.30%)	76 (0.37%)
PVD	6 (0.10%)	8 (0.02%)	951 (0.07%)	19 (0.09%)
Coronary disease <sup>6</sup>	67 (1.10%)	178 (0.46%)	11356 (0.85%)	170 (0.83%)
<b>Total cardiovascular disease</b>	<b>89 (1.46%)</b>	<b>291 (0.75%)</b>	<b>16129 (1.21%)</b>	<b>264 (1.29%)</b>
<b>Fractures<sup>2</sup></b>				
Hip fracture	7 (0.12%)	29 (0.07%)	2892 (0.22%)	27 (0.13%)
<b>Outcomes through Extension Study 2010-2020</b>				
<b>Number randomized</b>	583	3663	111511	1877
<b>Mean follow-up (months)</b>	161.3	166.3	194.8	170.6
<b>Cancer</b>				
Breast cancer	32 (0.41%)	245 (0.48%)	10042 (0.55%)	126 (0.47%)
Invasive breast cancer	27 (0.34%)	203 (0.40%)	8404 (0.46%)	104 (0.39%)
In situ breast cancer	6 (0.08%)	45 (0.09%)	1784 (0.10%)	24 (0.09%)
Ovarian cancer	2 (0.03%)	14 (0.03%)	975 (0.05%)	10 (0.04%)
Endometrial cancer <sup>7</sup>	1 (0.03%)	23 (0.07%)	1439 (0.13%)	25 (0.16%)
Colorectal cancer	10 (0.13%)	44 (0.09%)	2294 (0.13%)	34 (0.13%)
Other cancer <sup>8</sup>	42 (0.54%)	220 (0.43%)	12823 (0.71%)	177 (0.66%)
<b>Total cancer</b>	<b>83 (1.06%)</b>	<b>505 (0.99%)</b>	<b>25196 (1.39%)</b>	<b>337 (1.26%)</b>
<b>Deaths</b>				
Cardiovascular deaths	36 (0.46%)	149 (0.29%)	8491 (0.47%)	133 (0.50%)
Cancer deaths	29 (0.37%)	164 (0.32%)	8726 (0.48%)	123 (0.46%)
Other known cause	52 (0.66%)	132 (0.26%)	9538 (0.53%)	119 (0.45%)
Unknown cause	4 (0.05%)	19 (0.04%)	1752 (0.10%)	19 (0.07%)
<b>Total death<sup>9</sup></b>	<b>220 (2.13%)</b>	<b>971 (1.39%)</b>	<b>42074 (2.01%)</b>	<b>708 (2.06%)</b>

<sup>1</sup> The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

<sup>2</sup> Cardiovascular diseases and hip fracture are not adjudicated for SRC Super Cohort participants during the WHI Extension Study 2010-2020. Reported statistics represent experience during the original program and the Extension Study 2005-2010.

<sup>3</sup> "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Study 2005-2010.

<sup>4</sup> "CHD death" includes definite and possible CHD death.

<sup>5</sup> Angina and CHF are not verified outcomes in the WHI Extension Study 2005-2010. Reported statistics represent experience during the original program.

<sup>6</sup> "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, and CABG/PTCA; Q-wave MI, angina and congestive heart failure were not collected in the WHI Extension Study 2005-2010.

<sup>7</sup> Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

<sup>8</sup> Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

<sup>9</sup> Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.